UCLA

Continuous cardiac rhythm monitoring via cardiac implantable electronic devices and other wearable monitors has identified an increased number of patients with asymptomatic atrial fibrillation. However, not all patients with device-detected AHREs are alike, and fine-tuning risk assessment may help identify those patients that benefit the most from anticoagulation.”